

# 利用重組酵母菌生產玻尿酸

游植偉、李泰林

E-mail: 9801338@mail.dyu.edu.tw

## 摘要

玻尿酸(hyaluronan或hyaluronic acid, 簡稱HA)又稱透明質酸, 由葡萄糖醛酸-N-乙醯氨基葡萄糖為雙醣單位組成的直鏈聚合物, 是一種應用廣泛且深具潛力的生物高分子。其具有相當高的保水性、生物相容性及粘性等特性, 使得玻尿酸目前廣泛的應用於眼科、關節炎、整形手術及美容保養品。由於玻尿酸應用廣泛, 市場需求量越來越高, 但傳統的生產方法以從動物組織(如牛眼及雞冠)萃取的方式, 由於取得原料來源有限造成產量低且生產成本極高, 因此近年來發展出了以微生物發酵生產玻尿酸的方法。而所利用的微生物有Lancefield氏A群及C群鏈球菌, 在這種菌株中的玻尿酸是以莢膜(capsule)的型式存在, 而莢膜與菌體的致病性有很大的關係。因此鏈球菌應用於大規模生產時均篩選不具致病力的突變株進行培養。但是不具致病力的突變菌株, 生產玻尿酸的能力會有所降低; 此外發酵過程中是否殘留外毒素、內毒素等有害物質亦不容忽視, 且動物中可能含有透明質酸分解酵素(hyaluronidase), 因而降低萃取之透明質酸之分子量。因此科學界希望找尋其他適合的菌種來生產玻尿酸。因此本研究使用了長時間被人利用生產重組蛋白的啤酒酵母菌(*Saccharomyces cerevisiae*)來改善以上缺點; 分別送入hasB、hasC、IRES、has2及ADH1 promoter構築於兩個表現載體, 並將此兩個表現載體送入酵母菌中經由篩選之菌株希望可生產玻尿酸, 並探討酵素輔因子、受質及短鏈玻尿酸為引子對於產量之影響。實驗結果得知構築完成之啤酒酵母胞內的glucuronic acid產量為42.5 mg/L, 高於未構築之啤酒酵母菌胞內的glucuronic acid產量32.9 mg/L, 而當於培養基中添加入輔因子MgCl<sub>2</sub>與受質glucosamine時, 於隨機挑選之菌株中有最高的glucuronic acid產量57.6 mg/L, 而短鏈玻尿酸為引子並未使延長合成玻尿酸分子量, 因此可知於培養基中加入MgCl<sub>2</sub>與glucosamine對於玻尿酸產量是有幫助的。

關鍵詞: 玻尿酸, 啤酒酵母菌

## 目錄

封面內頁 簽名頁 授權書.....	iii	中文摘要.....	iv	英文摘要.....	iv
要.....	vi	誌謝.....	viii	目錄.....	x
目錄.....	xiv	表目錄.....	xv	1. 研究主題及動機.....	1
1.1 研究主題.....	1	1.2 研究動機.....	3	2. 文獻討論.....	5
2.1 玻尿酸之簡介.....	5	2.2 玻尿酸之結構.....	5	2.2.1 玻尿酸之一級結構.....	5
2.2.2 玻尿酸之二級結構.....	6	2.2.3 玻尿酸之三級結構.....	6	2.3 玻尿酸之性質.....	7
2.3.1 玻尿酸之保水性.....	7	2.3.2 玻尿酸之相容性及生物可吸收性.....	7	2.3.3 玻尿酸之黏彈性.....	7
2.3.4 玻尿酸之膨潤性.....	8	2.4 玻尿酸之應用.....	9	2.4.1 玻尿酸在眼科之應用.....	9
2.4.2 玻尿酸在關節疾病之應用.....	9	2.4.3 玻尿酸在傷口癒合之應用.....	10	2.4.4 玻尿酸在藥物釋放之應用.....	11
2.4.5 玻尿酸在臨床診斷之應用.....	11	2.4.6 玻尿酸在化妝品領域之應用.....	12	2.4.7 玻尿酸在整形手術之應用.....	12
2.5 鏈球菌病原性質與玻尿酸之關係.....	13	2.6 玻尿酸之來源.....	14	2.7 玻尿酸合成?.....	15
2.7.1 哺乳動物玻尿酸合成?之差異.....	15	2.7.2 微生物玻尿酸合成?.....	16	2.8 玻尿酸之生產方式.....	16
2.8.1 動物組織萃取製備玻尿酸.....	16	2.8.2 微生物發酵生產玻尿酸.....	17	2.9 玻尿酸之生化合成.....	18
2.10 酵母菌之蛋白質轉譯及RNA轉錄系統.....	19	2.10.1 啤酒酵母菌含有IRES的序列.....	19	2.10.2 啤酒酵母菌可產生UDP-N-acetyl-glucosamine.....	19
2.10.3 持續性表現啟動子.....	20	3. 實驗方法.....	22	3.1 材料.....	23
3.2 實驗方法.....	24	3.2.1 小鼠組織RNA萃取.....	24	3.2.2 反轉錄聚合?連鎖反應.....	25
3.2.3 啤酒酵母菌cDNA萃取.....	25	3.2.4 化膿性鏈球菌gDNA萃取.....	26	3.2.5 聚合?連鎖反應.....	27
3.2.6 洋菜膠體電泳.....	27	3.2.7 從洋菜膠體中洗提出DNA片段.....	28	3.2.8 核酸片段選殖.....	28
3.2.9 轉型作用選殖質體.....	29	3.2.9.1 勝任細胞製備.....	29	3.2.9.2 細胞熱休克轉型作用.....	29
3.2.9.3 質體DNA小量製備.....	30	3.2.10 表現載體構築.....	30	3.2.10.1 構築基因於表現載體pKL3.....	30
3.2.10.2 構築基因於表現載體pTEF1.....	31	3.2.11 高電壓脈衝的電穿孔法.....	32	3.2.12 基因重組菌體培養.....	33
3.2.13 分析方法.....	33	3.2.13.1 玻尿酸含量分析.....	33	3.2.13.2 膠體電泳分	

析.....	34	4. 實驗結果.....	35	4.1 利用PCR技術選殖基因.....	35	4.2 基因定序及序列比對.....	35	4.3 構築基因於表現載體pKL3.....	36	4.4 構築基因於表現載體pTEF1.....	36	4.5 宿主轉形作用.....	37	4.6 不同的培養成分對於重組菌株生產玻尿酸之影響.....	38	4.7 不同的菌株對於重組菌株生產玻尿酸之影響.....	38	4.8 膠體電泳之觀察結果.....	38	5. 討論.....	39	5.1 基因構築之比對結果.....	39	5.2 不同培養基成分對於玻尿酸產量之影響.....	39	5.3 不同的菌株對於重組菌株生產玻尿酸之影響.....	40	5.4 以基因改造微生物生產玻尿酸之研究.....	41	6. 結論.....	43	參考文獻.....	62	附錄.....	70
--------	----	--------------	----	----------------------	----	--------------------	----	------------------------	----	-------------------------	----	-----------------	----	--------------------------------	----	------------------------------	----	--------------------	----	------------	----	--------------------	----	----------------------------	----	------------------------------	----	---------------------------	----	------------	----	-----------	----	---------	----

## 參考文獻

- 參考文獻 1. 王盈錦和張淑貞。2001。高分子生醫材料。化工技術 9:110-129。 2. 王毅和鄭文艷。2005。玻尿酸製劑的臨床應用發展。食品與藥品7:11-16。 3. 李小迪。1997。透明質酸的保溼特性以其在化妝品的應用。香料香精化妝品3:19-22。 4. 李文任、黃偉蹈和黃雄飛。2003。關節腔內注射透明質酸鈉治療膝關節骨性關節炎。現代臨床醫學生物工程學雜誌9:263。 5. 沈慧彥。2006。培養基中碳氮源對獸疫鏈球菌發酵產程生成透明質酸之影響。大葉大學生物產業科技碩士班。碩士論文。 6. 姚敏傑、安海平和陳玉銘。1995。透明質酸發酵法製備研究。江蘇食品與發酵2:19-25。 7. 倪杭生、李潤、賀豔麗和羅敏。2001。透明質酸的離子交換層析純化。中國生化藥物雜誌32:485-487。 8. 徐紅和陸至華。1998。透明質酸鈉在化妝品中的應用。中國生化藥物雜誌19:222-223。 9. 高海軍、陳監、管失眾、堵國城和倫世儀。1999。獸疫鏈球菌搖瓶發酵法生產透明質酸。無錫輕工大學報18:17-22。 10. 凌沛學、賀豔麗、和張青。2005。透明質酸對骨關節炎的治療作用。食品與藥品。7:1-3。 11. 劉文斌、溫耀和孫思勤。2003。深層鞏膜切除聯合Healon GV 注入治療開角形青光眼。眼科研究21:189-190。 12. 陳鵬、陸文雄、周勤夫和嚴雅靜。1999。透明質酸的應用及製備研究發展。上海大學學報5:69-73。 13. 郭學平、王春喜、凌沛學和張天民。1998。透明質酸及其發酵生產概述。中國生化藥物雜誌19:209-212。 14. 馮建成、李潔、石衍君、金義鑫、袁琳和楊豔燕。2004。微生物發酵法生產透明質酸。現代商貿工業3:47-50。 15. 黃定國。2001。透明質酸之開發與應用。菌種保存及研究簡訊14:1-9。 16. 黃怡倩。2006。環境因子對獸疫鏈球菌發酵產程生成透明質酸之影響。大葉大學生物產業科技碩士班。碩士論文。 17. 張效良、劉隆躍和吳功柱。1999。人臍帶透明質酸製備及理化性質分析。中國藥房10:10-11。 18. 張魯榕、殷尉悵和孫淑潔。1991。血清透明質酸含量測定在肝病時的診斷意義。北京醫學。13:119-122。 19. 潘建名。2008。利用重組大腸桿菌生產玻尿酸。大葉大學分子生物科技學系碩士班。碩士論文 20. 蔡曉雯。2001。應用於組織工程之天然高分子-透明質酸。生物產業12:276-282。 21. 鄭曉龍、賀玲和楊新光。2002。透明質酸鈉在眼科的應用。實用醫學雜誌19:387-388。 22. 鄭雅雯。2004。在大腸桿菌表現系統表現Streptococcus zooepidemicus HAS 蛋白質。國立交通大學生化工程研究所。碩士論文。 23. 糜福龍、邱秀娟和陳俊瑜。2005。天然高分子生物醫用材料在化妝品領域之應用。化工技術13:155-164。 24. 顧其勝、王文斌和吳萍。1998。醫用透明質酸鈉在臨床中的應用綜述。中國修復重建外科雜誌12:124-126。 25. 羅曼和蔣立科。1999。牛眼透明質酸的分離及性質測定。生物化學與生物物理進展26:596-600。 26. 羅瑞明、郭美錦、儲炬和張嗣良。2003。高產大分子量透明質酸突變株NUF-036的選育。無錫輕工大學學報22:14-17。 27. 蕭至君。2003。利用大腸桿菌生產透明質酸之研究。國立陽明大學醫學工程研究所。碩士論文。 28. Armstrong, D. C. and Johns, M. R. 1997. Culture conditions affect the molecular weight properties of hyaluronic acid produced by Streptococcus zooepidemicus. Applied and environmental microbiology. 63: 2759-2764. 29. Armstrong, D. C., Cooney, M. J. and John, M. R. 1997. Growth and amino acid requirements of hyaluronic acid producing Streptococcus zooepidemicus. Applied Microbiology and Biotechnology. 47: 309-312. 30. Ashbaugh, C. D. and Sebastian A. 1998. Molecular analysis of the capsule gene region of group A Streptococcus: the hasAB genes are sufficient for capsule expression. Journal of Bacteriology. Sept: 4955-4959 31. Balaz, E. A. 1979. Ultrapure hyaluronic acid and the use therefore. United States Patent: 4,141,973. 32. Barker, S. A. and Young, N. M. 1966. Isolation of hyaluronic acid by gel filtration on agarose. Carbohydr. Res. 2: 363-370. 33. Bergan, T. and Hovig, B. 1969. Hyaluronic acid capsule in a Streptococcus faecalis Var. zymogenes a comparison with related mucoid strains. Acta. Pathol. Microbiol. Scand. 75: 97-103. 34. Bracke, J. W., Minnetonka, M. N., Thacke, K. and Minneapolis, M. N. 1985. Hyaluonic acid form bacterial culture. United States Patent: 4,517,295. 35. Bulik, D. A., Olczak, M., Lucero, H. A., Osmond, B. C., Robbins, P. W., and Specht, C. A. 2003. Chitin Synthesis in Saccharomyces cerevisiae in Response to Supplementation of Growth Medium with Glucosamine and Cell Wall Stress. Eukaryotoc. 2: 886-900. 36. Chong, B. F. and Nielsen, L. K. 2003. Aerobic cultivation of Streptococcus zooepidemicus and the role of NADH oxidase. Biochemical Engineering Journal. 16: 153-162. 37. Chung, J. H., Kim, H. J., Fagerholmb, P. And Cho, B. C. 1996. Effect of topically applied Na-hyaluronan on experimental corneal alkali wound healing. Korean J. Ophthalmol. 10: 68-75. 38. Cifonelli, J. A., Rebers, P. A. and Heddleston, K. H. 1970. The isolation and characterization oh hyaluronic acid form Pasteurella multocida. Carbohydrate Research. 14: 272-276. 39. Cleary, P. P. and Larkin, A. 1979. Hyaluronic acid capsule strategy for oxygen resistance in group A Streptococci. J. Bacteriol. 140: 1090-1097. 40. Crater, D. L., Dougherty, B. A., Van de Rijn, I. 1995. Molecular characterization of hasC form an operon required for hyaluronic acid synthesis in group A Streptococci. J. Biol. Chem. 270: 28676-28680. 41. Day, R., Brooks, P., Conaghan, P. G. and Petersen, M. 2004. A double blind randomized multicenter parallel group study of the effectiveness and toleramce of intraarticular hyaluronan in osteoarthritis of the knee. J. Rheumatol. 31: 775-782. 42. DeAngelis, P. L., Papaconstantinou, J. and Weigel, P. H. 1993. Isolation of a Streptococcus pyogenes gnen locus that directs hyaluronan biosynthesis in acapsular mutants and in heterologous bacteria. The Journal of Biological Chemistry. 268: 14568-14571. 43. Dostal, G. H. and Gamelli, R. L. 1993 Fetal wound healing. Surg. Gynecol. Obstes. 176: 299-306. 44. Dougherty, B. A., Van de Rijn, I. 1994.

Molecular characterization of hasA form an operon required for hyaluronic acid synthesis in group A Streptococci. *J. Biol. Chem.* 269: 169-175.

45. Dougherty, B. A., Van de Rijn, I. 1993. Molecular characterization of hasB form an operon required for hyaluronic acid synthesis in group A Streptococci. *J. Biol. Chem.* 268: 7118-7124.

46. Giusti, P., Lazzeri, L. and Lelli, L. 1993. Bioartificial polymeric materials a new method to design biomaterials by using both biological and sythetic polymers. *Trends. Polymer. Sci.* 1: 261-266.

47. Goldbergn, R. L., Huff, J. P., Lenz, M. E., Glickman, P., Katz, R. And Thonar, E. J. M. 1991. Elevated plasma levels hyaluronate in patients with osteoarthritis and rheumatoid arthritis. *Arthritis Rheum.* 34: 799-807.

48. Hascall, V. C. and Laurent, T. C. 1997. Hyaluronan: structure and physical properties. <http://www.glycoforum.gr.jp>

49. Hascall, V. C. 1997. Interaction of cartilage proteoglycans with hyaluronic acid. *J. Supramol. Struct.* 7: 101-120.

50. Hasegawa, S., Nagatsuru, M., Shibutani, M., Yamamoto, S. and Hasebe, S. 1999. Productivity of concentrated hyaluronic acid using a maxbled fermentor. *J. Biosci. Bioeng.* 88: 68-71.

51. Heldin, P., Asplund, T., Ytterberg, D., Thelin, S. and Laurent, T. C. 1992. Characterization of the molecular mechanism involved in the activation of hyaluronan synthetase by platelet-derived growth factor in human mesothelial cells. *Biochem. J.* 283: 165-170.

52. Heldin, P. and Laurent, T. C. 2000. Biosynthesis of hyaluronan. In: carbohydrates in chemistry and biology. (Ernst B, Hart G, Sinay P, Eds.), Vol. 3, p. 363-372, Wiley/WCH, Weinheim.

53. Huang, L. L. 1994 Development of hyaluronan collagen fibrillar matrices. *Chinese J. Med. Biol. Eng.* 14: 53-56.

54. John, M. R., Goh, L. T., and Oeggri, A. 1994. Effect of pH, agitation and aeration on hyaluronic acid production by *Streptococcus zooepidemicus*. *Biotechnology letters.* 16: 507-512.

55. Kim, J. H., Yoo, S. J., Oh, D. K., Kweon, Y. G., Park, D. W., Lee, C.H. and Gill, G. H. 1996. Selection of a *Streptococcus equi* mutant and optimization of culture conditions for the production of high molecular weight hyaluronic acid. *Enzyme and Microbial Technology.* 19: 440-445.

56. Laurent, T. C. 1987. Biochemistry of Hyaluronan. *Acta. Otolaryngol. (Stockn) Suppl.* 442: 7-24.

57. Laurent, T. C., Laurent, U. B. And Fraser, J. R. 1996. Serum hyaluronan as a disease marker. *Ann Med.* 28: 241-253.

58. Laurent, T. C., and Fraser, J. R. E. 1986. The properties and turnover of hyaluronan. In: function of the proteoglycans (Evered D, Whelan J, Eds) cida foundation symposium 124, pp9-29, New York. Wiley.

59. Laurent, T. C. and Fraser, J. R. E. 1992. Hyaluronan. *FASEB J.* 6: 2397-2404.

60. Lazzeri, L., Barbani, N., Cascone, M. G., Lupinacci, D. and Giusti, P. 1994. Physicochemical and mechanical characterization of hydrogels of poly(vinyl achol) and hyaluronic acid. *J. Mater. Sci. Mater. Med.* 5: 862-867.

61. Liu, L. S., Ng, C. K., Thompson, A. Y., Poser, J. W. and Spiro, R. C. 2002. Hyaluronate heparin conjugate gels for the delivery of basic fibroblast growth factor (FGF-2). *J. Biomed. Master. Res.* 62: 128-135.

62. Markovitz, A. and Dorfman A. 1962. Synthesis of capsular polysaccharide (hyaluronic acid) by protoplastmembrane preparations of group A Streptococcus. *J. Biol. Chem.* 237: 273-279.

63. McLennan, A. P. 1956. The production of capsules, hyaluronic acid and hyaluronidase by 25 strain of group C Streptococci. *The Journal of General Microbiology.* 15: 485-491.

64. Meyer, K. and Palmer, J. 1934. The polysaccharide of the vitreous humor. *J. Biol. Chem.* 107: 629-634.

65. Miler, D. and Stegman, R. 1980. Usa of sodium hyaluronate in anterior segment eye surgery. *American Intra-Ocular Implant Society Journal.* 6: 13-15.

66. Morimoto, K., Metsugi, K., Katsumata, H., Iwanaga, K. And Kakemi, M. 2001. Effects of low viscosity sodium hyaluronate preparation on the pulmonary absorption of rhinsulin in rats. *Drug. Dev. Ind. Pharm.* 27: 365-371.

67. Itano, N., Sawai, T., Yoshida, M., Lenas, P., Yamada, Y., Imagawa, M., Shinomura, T., Hamaguchi, M., Yoshida, Y., Ohnuki, Y., Miyauchi, S., Spicer, A. P., McDonald, J. A. and Kimata K. 1999. Three Isoforms of Mammalian Hyaluronan Synthases Have Distinct Enzymatic Properties. *J. Bio. Chem.* 274: 25085 – 25092.

68. Nimrod, A., Greenman, B., Kanner, D. and Landsberg, M. 1998. High molecular weight sodium hyaluronate. United States Patent : 4,784,990.

69. Prehm, P. 1983. Synthesis of hyaluronate in differentiated teratocarcinoma cells characterization of the synthase. *Biochem. J.* 211: 181-189.

70. Prestwich, G. D., Marecak, D. M., Marecek, J. F., Vercrusse, K. P. and Ziebell, M. R. 1998. Controlled chemical modification of hyaluronic acid : synthesis, applications, and biodegradation of hydrazide derivatives. *J. Control. Release.* 53: 93-103.

71. Roseman , S., Mose, F. E., Ludowieg, J. and Dorfman, A. 1953. The biosynthesis of hyaluronic acid by group A Streptococcus. I. utilization of 1-C14-Glucose. *J. Biol. Chem.* 203: 213-225.

72. Schulz T., Schumacher U. and Prehm P. 2007. Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. *J. Biol. Chem.* 282: 20999-21004.

73. Scott, J. E. 1998. Secondary and tertiary structures of hyaluronan in aqueous solution. <http://www.glycoforum.gr.jp>

74. Slevin, M., Kumar, S. and Gaffney, J. 2002. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. *J. Biol. Chem.* 277(43): 41046-41059.

75. Sten, S. 2000. Method and means for the production of hyaluronic acid. United States Patent : 6,090,596.

76. Sugahara, K., Schwartz, N. B. and Dorfman, A. 1979. Biosynthesis of hyaluronic acid by *Streptococcus*. *J. Biol. Chem.* 254: 6252-6261.

77. Thonard, J. C., Migliore, S. A. and Blustein, R. 1964. Isolation of hyaluronic acid form broth cultures of Streptococci. *J. Bio. Chem.* 239: 726-728.

78. Warren, G. H. and Gray, J. 1959. Isolation and purification of streptococcal hyaluronic acid. *Proc. Soc. Exp. Biol. Med.* 102: 125-127.

79. Weissmann, B. and Meyer, K. 1954. The structure of hyaluronic acid and hyaluronic acid form umbilical cord. *J. Am. Chem. Soc.* 76: 1753-1757.

80. Wessels, M. R., Goldberg, J. B., Moses, A. E. and DiCesare, T. J. 1994. Effects on virulence of mutations in a locus essential for hyaluronic acid capsule expression in group A Streptococci. *Infection and Immunity.* 62: 433-441.

81. Whistler, R. L. 1965. Chapter 5. Hyaluronic acid. In: Carbohydrate Chemistry. Academic Press, London, UK, p. 43-63.

82. Whitnack, E., Bison, A. L. and Beachy, E. H. 1981. Hyaluronate capsule prevents attachment of group A Streptococci to mouse peritoneal macrophages. *Infection and Immunity.* 31: 985-991.

83. Zhou, W., Edelman, G. M. and Mauro, V. P. 2000. Transcript leader regions of two *Saccharomyces cerevisiae* mRNAs contain internal ribosome entry sites that function in living cells. *Natl Acad Sci.* 98: 1531 – 1536.